Hidradenitis Suppurativa

Panelists discuss how societal factors like embarrassment and limited health care access contribute to diagnostic delays of 6 to 7 years despite HS being clinically straightforward to identify and describe the profound impact on patients’ lives beyond sterile quality of life measures, including loss of relationships, careers, and life milestones.

Panelists discuss how HS develops from a combination of genetic predisposition and environmental exposures, leading to immune-based inflammation in skin folds, and explain clinical diagnosis methods, including Hurley staging and assessment of inflammatory lesions.

These phase 3 data, released by MoonLake Immunotherapeutics, highlight week 16 results for patients with hidradenitis suppurativa using sonelokimab.

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

In this analysis, the degree to which each dermatological condition impacts biological aging was highlighted using epigenetic clocks.

Investigators explored the characteristics of pediatric-onset hidradenitis suppurativa, emphasizing the need for earlier detection to expedite diagnosis.

This analysis highlights the global prevalence of HS and some of the most significant global variations in HS prevalence.

The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

These data point to several hidradenitis suppurativa drugs as most impactful for those with moderate-to-severe disease, based on Hidradenitis Suppurativa Clinical Response.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

This session with Ginette Okoye, MD, features a discussion about hidradenitis suppurativa (HS) and several helpful approaches for patients.

This video includes a discussion of different procedures designed to help treat patients with hidradenitis suppurativa (HS) and atopic dermatitis.

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

This prospective observational study suggests that there are differences between the gut microbiome compositions of pediatric patients and others with HS.

In this cross-sectional study, investigators looked at the relationship between neighborhood-level socioeconomic status and hidradenitis suppurativa.

This episode of the SOCS podcast features an in-depth discussion between Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy.

These data highlight the susceptibility loci shared between HS and other inflammatory diseases among those with this condition.